To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in South Korea (ECOS KOR)

Merck KGaA (EMD Serono)

Status: Completed

Conditions: Growth Disorders

Study type: Observational

Funder types: Industry

Identifiers

NCT01259778

EMR 200104-522

Details and patient eligibility

About

This is a National, Multicentre, Observational Registry to study Adherence and Long Term Outcomes of Therapy in paediatric subjects using easypod™ electromechanical device for growth hormone treatment from hospital in Korea in order to assess the level of adherence of subjects receiving SAIZEN® via easypod™.

Full description

Subjects will be enrolled in a multicenter, longitudinal, observational registry. Parents/subjects will provide their Informed Consent/assent to upload their data for population-based analyses and optionally to adhere to a patient adherence support program designed to improve their adherence and, ultimately, clinical outcomes. Adherence data will be primarily derived from the easypod™ device combined with physician data entry of outcome measures. Data will be collected retrospectively and prospectively. This will allow the establishment of adherence profiles and explore the hypothesis that patient adherence support programs improve adherence and subsequent clinical outcomes. Collected data will be also analyzed in a multinational pooled analysis of comparable national studies.

Primary Objective:

To assess the level of adherence of subjects receiving SAIZEN via easypod™

Secondary Objectives:

• To describe the impact of adherence on clinical outcomes for subject receiving SAIZEN via easypod™
• To identify adherence subject profiling
• To assess the impact of adherence on Insulin-like growth factor 1 (IGF-1) (i.e. above, below or within normal ranges)
• Temporal profile of IGF-1 and IGFBP-3 levels

Enrollment: 224 patients

Sex: All

Ages: 2 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Administered growth hormone via the easypod™ electromechanical device according to Summary of Product Characteristics (SmPC)
• Over the age of >2 years
• Under <18 years of age, or over 18 without fusion of growth plates
• Parent's or guardian's written informed consent, given before entering data into the registry, with the understanding that the subject or parent/guardian may withdraw consent at any time without prejudice to future medical care. If the child is old enough to read and write, a separate assent form will be given as defined in the appropriate jurisdiction of each country.

Exclusion criteria

• Subjects taking growth hormone in whom growth plates have fused (i.e. for taking growth hormone for it's metabolic effects)
• Contra-indications to SAIZEN® as defined in the Summary of Product Characteristics (SmPC)
• Use of an investigational drug or participation in an interventional clinical study